In Understanding Cleanroom Apparel  Sterilization - Part 1, I discussed the   Method 1 validation protocol. The validation protocol is specified in  the ANSI/AAMI/ISO   11137-1:2006 document entitled “Sterilization of health care products –  Radiation – Part   1: Requirements for development, validation and routine control of a  sterilization   process for medical devices” and ANSI/AAMI/ISO 11137-2:2006  “Sterilization   of health care products – Radiation –Part 2: Establishing the  sterilization   dose. These documents address both Method 1 and VDmax (Verification  Dose Maximum)   methods to determine the device bioburden and perform a verification  dose experiment.   Specifically, the VDmax methods described in 11137-2:2006 are for  selected   sterilization doses of 25 kGy and 15 kGy. The method for 25 kGy is  applicable   to products having an average bioburden less than or equal to 1,000  CFUs (colony   forming units) per device. The method for 15 kGy is applicable to  products   having an average bioburden less than or equal to 1.5 CFUs per device.  Under   a new AAMI document for VDmax (AAMI TIR 33:2006), sterilization doses  can be   validated from 15 kGy to 35 kGy in 2.5 kGy increments. The VDmax  method is   based on the same concept as Method 1 and is now more commonly used  than Method   1 in the United States. It can be applied to any type of product that  can use   Method 1 and is widely accepted by the FDA. For comparison purposes, I  will discuss the procedure for Method VDmax25 for multiple production  batches.
Both     gamma irradiation sterilization validation protocols begin with  determining     the bioburden on the sample item proportion (SIP). The SIP is  generally 10%     of a medium cleanroom coverall because the product is too large for  the precise     performance of the required tests of sterility. This would also be  the justification   for the gamma sterilization validation of other cleanroom items that  are too   large for accurate performance of the required tests. In the VDmax25  method   described in Worked Example Table 31, a minimum of 40 samples are  required.   Ten devices from three separate production lots are washed with other  contaminated   garments, dried and packaged with these garments, and are submitted  for bioburden   determination. It is recommended that 20 samples be prepared from each  lot   in the event that the variance in bioburden between lots requires  subsequent   dose verification of a specific lot.    
The 30 samples are sent to a contract   laboratory to undergo exhaustive extractions for both the bioburden  and bioburden   validation testing. If the bioburden per   SIP is less than 30–50 CFUs per sample, another validation bioburden   validation approach may be necessary. These two tests are often  performed simultaneously.   Each sample is extracted multiple times (usually four) and the  extracts or   rinsates are filtered. The filter from each extraction is placed on an  agar   culture medium such as tryptic soy agar and incubated allowing the  total aerobic   bacteria and fungi CFUs to be counted. In the validation stage, the  counts   from the first extract for each sample are divided by the total from  all extractions   to determine the percentage or efficiency of recovery in the first  extraction.   A bioburden recovery factor is then calculated as the inverse of the  percentage   of recovery. This value is used to calculate the bioburden for each of  the   thirty samples and an average for each of the three lots is obtained.  These   numbers are later multiplied by 10, if the SIP is 10%, to determine  the number   of CFUs for the total device (coverall). As long as no single lot has  an average   more than twice, the overall average then the verification dose  experiment   can use 10 samples from any of the three lots. A chart (Table 9 for  average   bioburdens up to 1,000) in the “ANSI/AAMI/ ISO 11137-2-2006  Sterilization   of health care products – Radiation – Establishing the sterilization   dose” then indicates an SIP dose reduction factor that should produce   a biological reduction equal to that of the Method 1 sterilization  dose. 
The   ten additional samples previously prepared along with the thirty  samples tested   for bioburden are then sent to the contract sterilizer with an  instruction   to irradiate at the calculated verification dose for the SIP samples.  The samples   are then subjected to a test of sterility and cultured in tryptic soy  broth.   If there are one or zero positive samples per the ten sample lot, then  it can   be accepted and substantiate 25 kGy as the sterilization dose. If two  positives   are obtained then a confirmatory verification dose test is performed.  In this   test, ten additional samples are irradiated and tested exactly as  performed   previously. If there are zero positives in this confirmatory test, the  validation   passes and 25 kGy is substantiated. If any positives are obtained in  the confirmatory   test and no errors in testing or dosing can be confirmed, then 25 kGy  is not   substantiated and a higher dose must be validated (i.e., 27.5 kGy in  AAMI TIR   33-2006). Additionally, at the time of validation, a one-time  bacteriostasis/   fungistasis test is performed with product to assure an appropriate  sterility   test method was used.
NOTE: The VDmax method  calculates the verification dose   for 10 samples rather than 100 samples as used in Method 1. This  difference   in sample size is allowed   because the VDmax method targets a verification dose of
10-1while the Method 1 method targets a verification dose of 10-2.  This reduction   in sample size can result in large savings due to the smaller sample  size.
The   validated sterilization dose continues to be used as long as the  quarterly   dose audits continue to pass, the process stays in control and no  specifics   of the process changes. Any change in the process requires an  evaluation of   the potential impact that the change may have on the product bioburden  and   may require a complete re-validation. 
The calculated sterilization dose whether   determined by Method 1 validation or Method VDmax validation becomes  one component   of the customer specifications for gamma radiation of the product.  Other factors   are the density of the product, product dimensions, and the weight of  the product   in the transport container used. The contract sterilizer performs a  dose mapping   of each product. This assures that the correct radiation dose is  delivered   to every product in the box every time. Dosimeters are placed on the  product   during the gamma radiation process. After radiation the dosimeters are  removed   and read using a calibrated spectrophotometer. The product is released  by Quality   Assurance based on the dosime-try readings’ compliance with the  customer’s   specified minimum and maximum gamma dose for the product. 
It is incumbent for the supplier of  either reusable or disposable cleanroom   garments to validate its sterile garment program for gamma radiation  per ANSI/AAMI/ISO   11137-1:2006, “Sterilization of Health Care Products -Radiation – Part   1: Requirements for Development, Validation and Routine Control of a  Sterilization   process for medical devices” and ANSI/AAMI/ISO 11137-2:2006,  “Sterilization   of health care products – Radiation – Part 2: Establishing the   Sterilization Dose” and to assure its promise to deliver garments  sterilized to the contracted SAL by performing dose audits every three months. 
ANSI/AAMI/ISO   11137-1:2006, “Frequency of sterilization dose audits” states the   frequency of dose audits may be reduced to every six months if there  has not   been a change in the validated system and all quarterly dose audits  have passed   in the previous year. If there is a failure, dose audits must be  performed   every three months. Even if there has not been a change in the  validated system, dose audits must be performed at least once a year.
I thank Martell Winters, Nelson  Laboratories, and Gregg Mosley, Biotest Laboratories   for their technical assistance in writing and reviewing this column.
Jan Eudy is IEST Past-President.She is  also Corporate Q.A.Manager for Cintas   Cleanroom Resources.
validation refers to establishing documented evidence that a process or system, when operated within established parameters, can perform effectively and reproducibly to produce a medicinal product meeting its pre-determined specifications and quality attributes
Subscribe to:
Post Comments (Atom)
Pharmaceutical Validation Documentation Requirements
Pharmaceutical validation is a critical process that ensures that pharmaceutical products meet the desired quality standards and are safe fo...
- 
K. Dashora, D. Singh, Swarnlata Saraf and S. Saraf *. Institute of Pharmacy, Pt.RavishankarShuklaUniversity, Raipur 492 010. *Author for ...
 - 
Cold storage is a relatively simple cold room that is commonly used to store material between 2[degrees] to 8[degrees]C. Such cold rooms a...
 - 
Validation of the Autoclave is classified into the following 1.0 OQ – Operational Qualification 2.0 PQ – Performance Qualification The valid...
 
4 comments:
Thanks for sharing this knowledge about how garments are validated in the Pharmaceutical industry. Interesting read indeed!
Cheers!
Cleanroom Supplies Distributor
Thanks for sharing information
Cleanroom Solutions Hyderabad & Cleanroom Equipment in India
Thank you for providing such valuable information regarding gamma radiation sterilization. Keep posting and sharing!
Thank you for sharing such wonderful information I would like to recommend Symec Engineers gamma radiation sterilization in India. Keep posting and keep sharing!!
Post a Comment